Personalized medicine and CRISPR-Cas۹,a revolution in treatment of Multiple Myeloma

Background: Multiple myeloma (MM) is a type of blood cancerthat occurs due to the uncontrolled growth of plasma cells inbones and soft tissues of the body. Since advanced tools can predict,treat, and diagnose this disease quickly and timely, personalizedmedicine, a treatment method based on precise knowledgeof genetic, molecular, and individual disease information,according to the individual characteristics of the patient, it can be effective in the treatment of MM. Various methods are usedin this personalized medicine, among which CRISPR-Cas۹ hasbeen proposed as an effective tool to improve accuracy in thediagnosis and targeted treatment of various diseases in personalizedmedicine. Therefore, the aim of this study is to investigatethe results of the CRISPR-Cas۹ method for the diagnosisand treatment of multiple myeloma.Materials and Methods: In this review study, relevant articleswere examined from various databases to evaluate the efficacyof the CRISPR-Cas۹ method in personalized medicine for predictingand treating individuals with multiple myeloma. Datawas extracted and collected for analysis.Results: The clinical trials have confirmed the effectiveness ofthe CRISPR-Cas۹ method in treating multiple myeloma, indicatingits potential for detecting MM gene expression, examiningdrug mechanisms, screening drug-resistant genes, developingimmunotherapy, and screening for new drug targets. Theresults indicate that CRISPR-Cas۹ has great potential in theclinical application of personalized medicine for MM.Conclusion: Although there are various treatments availablefor multiple myeloma, including chemotherapy, radiotherapy,cryotherapy, the use of antibodies, bone marrow transplantation,and more, none of these treatments can be effective forall patients due to the complexity and challenging nature ofMM. Therefore, new methods such as CRISPR-Cas۹, which isa powerful tool for gene therapy, have been used to treat MM.It is predicted that this method can be used to treat each patientindividually based on their genetic sequence.

کلیدواژه ها:

Multiple Myeloma Cancer ، Personalized Medicine ، CRISPR-Cas۹ ، Immunotherapy